Stories

Drug policy and tobacco policy face the same core challenge: reducing harm in the real world, not demanding perfect behaviour. Whether the issue is illicit drugs, smoking or nicotine use, prohibition and stigma often push people further from support and safer choices. Harm reduction offers a shared solution by prioritising evidence, dignity and practical routes to lower risk. Public health should meet people where they are — and help them move towards safer outcomes.

New Zealand’s accelerated decline in smoking shows what can happen when safer nicotine alternatives remain accessible. As vaping became more widely available, smoking rates fell faster, suggesting that harm reduction can support progress where traditional tobacco control alone may not be enough. The lesson is clear: adults need realistic routes away from combustible cigarettes. Public health policy should protect that progress, not restrict the tools helping smokers leave smoking behind.

Most UK smokers now wrongly believe vaping is as harmful as, or more harmful than, cigarettes. That misunderstanding matters: if people cannot distinguish between combustible tobacco and lower-risk alternatives, they may be less likely to switch away from smoking. Vaping is not risk-free and should not be promoted to non-smokers, but misrepresenting relative risk protects cigarettes by default. Public health communication should be accurate enough to help smokers make better choices.

The FDA’s flavour policy increasingly appears disconnected from how adult smokers actually switch away from cigarettes. Flavours are not just a youth issue — for many adults, they help make vaping a workable alternative to combustible tobacco. If regulation removes the products people find acceptable, it may weaken harm reduction while leaving cigarettes widely available. Public health policy should reflect real-world behaviour, not assumptions that ignore why switching succeeds.

Survey findings suggest that many online nicotine pouch customers are using them as part of a move away from smoking or vaping. Nearly half reportedly tried pouches to quit, showing that smoke-free alternatives can play a role in real-world behaviour change. Policy should recognise why adults choose these products rather than assuming all use is the same. Harm reduction works best when regulation reflects consumer motivations, relative risk and practical routes away from more harmful products.

Nicotine addiction should be understood with nuance, not moral panic. Dependence is real, but it should not be confused with the harms caused by burning tobacco. For people who smoke, moving to lower-risk nicotine products can reduce exposure to the toxicants responsible for most smoking-related disease. Better policy starts by separating addiction, risk and harm — and by helping people make safer choices.

Kenya’s tobacco control bill should be guided by science, not fear. Regulation must protect young people, but it should also recognise the difference between combustible cigarettes and lower-risk nicotine alternatives. If safer products are restricted too heavily, adult smokers may be left with fewer realistic options to quit. Evidence-based policy should reduce harm, preserve informed choice and keep alternatives within legal, regulated markets.

Bad science becomes a public health problem when weak claims are repeated as certainty. In nicotine policy, flawed studies and exaggerated conclusions can distort risk perception, fuel moral panic and push regulation away from evidence. Vaping should be scrutinised, but criticism must be grounded in robust methods, fair comparisons and context on relative risk. Public health loses credibility when advocacy is dressed up as science.

The Maldives’ decision to make cigarettes cheaper raises serious questions about the consistency of tobacco policy. If public health advice is shaped by opaque studies and international pressure while lower-risk alternatives remain restricted, smokers may be left with the most harmful option made more affordable. Reducing harm requires transparent evidence, proportionate regulation and policies that distinguish between combustible tobacco and safer nicotine products. Public health should not protect cigarettes by default.

The FDA’s ruling on nicotine pouches is a major step towards honest relative-risk communication. By recognising that authorised smoke-free products can present lower risks than cigarettes, regulators are acknowledging what tobacco harm reduction has long argued: combustion is the central danger. Adult smokers need clear, accurate information about alternatives that may help them move away from cigarettes. Public health policy should make safer choices easier to understand, not harder to access.